Please provide your email address to receive an email when new articles are posted on . Preoperative chemoradiotherapy did not improve survival for individuals with resectable gastric cancer. The ...

Historically, the clinical staging of pancreatic cancer has centered on the surgical management of the primary tumor, because few effective chemotherapeutic agents were available and long-term ...

Adding nivolumab (Opdivo) to neoadjuvant chemotherapy followed by adjuvant treatment with the PD-1 inhibitor alone significantly increased event-free survival (EFS) for patients with resectable ...

Patients with borderline resectable pancreatic cancer (PDAC) are often treated with chemotherapy, radiotherapy, or both before undergoing surgery, but the optimal regimen in this setting is ...

Please provide your email address to receive an email when new articles are posted on . The FDA expanded the approval of durvalumab for lung cancer. The new indication applies to use of the agent with ...

For patients with newly diagnosed resectable brain metastases (BM), cesium-131 tile-based radiation therapy (TBRT), which ...

Findings from the phase 3 ESOPEC trial demonstrate an overall survival advantage with a perioperative chemotherapy regimen known as FLOT compared with a neoadjuvant chemoradiation approach, called ...

Tyvyt plus CRT achieved a 60% pCR rate, outperforming Tyvyt plus chemotherapy (13%) and CRT alone (47.3%). Neoadjuvant Tyvyt plus CRT may become a new standard of care for resectable, locally advanced ...

Ablative radiation therapy led to promising overall survival in patients with technically resectable pancreatic cancer who were high-risk candidates for surgery. The 2-year overall survival rate was ...

GRAND CAYMAN, Cayman Island--(BUSINESS WIRE)--Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...